Used in medical and pharmacological research to study the mechanism of the GPR40 receptor, also known as FFAR1, which is involved in blood sugar regulation. This receptor plays a crucial role in insulin secretion from the pancreas. As such, TUG770 serves as a potent and selective agonist in the development of novel anti-diabetic drugs. Furthermore, it is investigated for treating other metabolic disorders, including obesity and non-alcoholic fatty liver disease. Preliminary studies indicate that TUG770 enhances insulin sensitivity and reduces insulin resistance, potentially offering more effective therapies for type 2 diabetes patients.